Phaseline

Targets › PDK3

PDK3 ([Pyruvate dehydrogenase): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology.

Inhibits pyruvate dehydrogenase activity by phosphorylation of the E1 subunit PDHA1, and thereby regulates glucose metabolism and aerobic respiration. Can also phosphorylate PDHA2. (UniProt, Q15120)

Open in Phaseline: the race on PDK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Saol TherapeuticsSodium Dichloroacetate
Pyruvate dehydrogenase kinase inhibitor
PDK2, PDK3, PDK4, PDK1Phase 3Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme–

Conditions

Pyruvate Dehydrogenase Complex Deficiency (1) Glioblastoma Multiforme (1)

Modalities

mixed (1)

Companies

Saol Therapeutics (1)

Related targets

PDK2 (1) PDK4 (1) PDK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.